The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective
Authors
Keywords
Multiple myeloma, Oncology, Panobinostat, Relapsed, Relapsed and refractory
Journal
ADVANCES IN THERAPY
Volume 33, Issue 11, Pages 1896-1920
Publisher
Springer Nature
Online
2016-09-27
DOI
10.1007/s12325-016-0413-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
- (2016) A. Jakubowiak et al. BLOOD
- Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
- (2016) Rachid C. Baz et al. BLOOD
- Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity
- (2016) R F Cornell et al. BONE MARROW TRANSPLANTATION
- Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
- (2016) Niels W. C. J. van de Donk et al. IMMUNOLOGICAL REVIEWS
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment
- (2015) P. G. Richardson et al. BLOOD
- Inflammation rapidly reorganizes mouse bone marrow B cells and their environment in conjunction with early IgM responses
- (2015) J. M. Moreau et al. BLOOD
- SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide
- (2015) H Jiang et al. LEUKEMIA
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
- (2015) Marije B Overdijk et al. mAbs
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1
- (2014) M. Mraz et al. BLOOD
- Abstract 4735: SAR650984: Characterization of a potent phase I humanized anti-CD38 antibody for the treatment of multiple myeloma and other hematologic malignancies.
- (2014) Marie-Cécile Wetzel et al. CANCER RESEARCH
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
- (2014) S Vincent Rajkumar et al. LANCET ONCOLOGY
- Current treatment landscape for relapsed and/or refractory multiple myeloma
- (2014) Meletios A. Dimopoulos et al. Nature Reviews Clinical Oncology
- PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
- (2013) P. G. Richardson et al. BLOOD
- Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
- (2013) M. F. Kaiser et al. BLOOD
- Carfilzomib
- (2013) K. M. Kortuem et al. BLOOD
- Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors
- (2013) J Moreaux et al. BRITISH JOURNAL OF CANCER
- Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC
- (2013) Sridurga Mithraprabhu et al. BRITISH JOURNAL OF HAEMATOLOGY
- Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC
- (2013) Shauna M. Collins et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study
- (2013) Meletios Dimopoulos et al. LANCET ONCOLOGY
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
- (2013) Jesus San Miguel et al. LANCET ONCOLOGY
- Association of response endpoints with survival outcomes in multiple myeloma
- (2013) S Lonial et al. LEUKEMIA
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
- (2013) Ken Maes et al. Cancers
- Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
- (2012) Laurent Garderet et al. JOURNAL OF CLINICAL ONCOLOGY
- Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia
- (2011) M. J. Bishton et al. BLOOD
- A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma
- (2011) J. A. Zonder et al. BLOOD
- Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
- (2011) Y. X. Zhu et al. BLOOD
- Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies
- (2011) E. C. Lee et al. CLINICAL CANCER RESEARCH
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
- (2011) S K Kumar et al. LEUKEMIA
- Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma
- (2011) T. Hideshima et al. MOLECULAR CANCER THERAPEUTICS
- Multiple Myeloma
- (2011) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
- (2010) J. Kikuchi et al. BLOOD
- Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
- (2010) B. A. Walker et al. BLOOD
- Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer
- (2010) E. Kupperman et al. CANCER RESEARCH
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
- Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes
- (2010) C R Giver et al. LEUKEMIA
- Polycomb Target Genes Are Silenced in Multiple Myeloma
- (2010) Antonia Kalushkova et al. PLoS One
- The potential role of epigenetic therapy in multiple myeloma
- (2009) Emma M. Smith et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges
- (2009) Peter Atadja CANCER LETTERS
- In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myeloma
- (2009) E. M. Ocio et al. HAEMATOLOGICA
- Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
- (2009) M A Dimopoulos et al. LEUKEMIA
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search